TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04432493

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation (rTMS)
Description: Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation (rTMS)
Description: Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
Study: NCT02438956

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Setria glutathione supplement
Description: 500 mg/day capsule taken in the morning for 120 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystalline Cellulose
Description: 500 mg/day capsule taken in the morning for 120 days.
Study: NCT02209402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
Study: NCT03820453

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tribulus Terrestris
Description: The experimental arm will receive a dietary supplement to increase the libido and sexual function

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: The control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics
Study: NCT01449110

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in primary cardiovascular prevention (PP)
Description: 12 months follow-up:~1. capsule/day of placebo (350 mg maltodextrin) for 6 months~2. capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in secondary prevention
Description: 12 months follow-up:~1. capsule/day (350 mg maltodextrin) for 6 months~2. capsules/day (350 mg + 350 mg maltodextrin) for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape extract in primary prevention (PP)
Description: 12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape extract in SP
Description: 12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol-enriched grape extract in PP
Description: Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol-enriched grape extract in SP
Description: Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months
Study: NCT00537732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: 20 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: 20 vs. 60 mg daily, genotype dependent
Study: NCT02720601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan & Capecitabine
Description: Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
Study: NCT02115841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enraf-Nonius Muscle stimulator
Description: The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enraf-Nonius Muscle stimulator
Description: The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
Study: NCT03051984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (\~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
Study: NCT02073032

Intervention type: OTHER
Intervention: No intervention, only observation
Study: NCT02485652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: 800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.
Study: NCT04963114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: art therapy
Description: guided art tour and workshop
Study: NCT04199104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
Study: NCT04248543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: qMRI with Gadoteridol contrast agent
Description: quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.
Study: NCT04261686

Intervention type: DEVICE
Group type: OTHER
Intervention: Covera Vascular Covered Stent
Description: This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent
Study: NCT01758328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study: NCT03724539

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Patients being assigned to the control arm will be treated in accordance with standard care. They will receive a sham intervention, which consists of a usual medication review by their GP and a shared decision making between patient and GP.
Study: NCT03914781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIN-SELF Program
Description: The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
Study: NCT04461171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery
Description: Undergo an enhanced recovery after surgery program
Study: NCT02905331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
Study: NCT03255486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study).
Study: NCT04106986

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field and Progressives resistance exercise
Description: The pulsed electromagnetic field treatment consist of 30 minutes pulsed electromagnetic field with 50 Hz pulses~The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRE
Description: The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al.
Study: NCT01744990

Intervention type: OTHER
Group type: OTHER
Intervention: Oral food challenges to multiple nuts
Study: NCT02260050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL 801 CL dry syrup new formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WAL 801 CL dry syrup conventional formulation
Study: NCT00815945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegLiposomal Doxorubicin
Description: PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
Study: NCT00411645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maribavir
Description: 100 mg twice daily for up to 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice daily for up to 12 weeks
Study: NCT01758328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin (ATG)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a T cell depleted stem cell transplant
Study: NCT04469920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 2 mg
Description: 1 tablet, single dose at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 2 mg
Description: 1 tablet, single dose at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 2 mg
Description: 1 tablet, single dose at Day 1
Study: NCT02326753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No. 7 oral airway
Description: the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No. 8 oral airway
Description: the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No. 9 oral airway
Description: the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
Study: NCT02956265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bimodal optical spectroscopy
Description: an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra
Study: NCT04469920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: 1 tablet, single dose at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: 1 tablet, single dose at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: 1 tablet, single dose at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: 1 tablet, single dose at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: 1 tablet, single dose at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: 1 tablet, single dose at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: 1 tablet, single dose at Day 1
Study: NCT03839485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic treatment using Guedes-Pinto Paste
Description: Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endodontic using Guedes-Pinto Paste without antibiotic
Description: Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
Study: NCT02743806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion
Study: NCT02615587

Intervention type: DRUG
Intervention: Standard of care in AF in Denmark
Description: As used in clinical practice, analysed as per drug class, not separate drugs.
Study: NCT00597545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid endarterectomy
Description: When a shunt is inserted to increase blood flow to the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Description: When a shunt is inserted to increase blood flow to the brain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shunt
Description: A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shunt
Description: A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
Study: NCT00111592

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: current usual care
Description: current usual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment protocol with clear indications for therapy
Description: treatment protocol with clear indications for therapy
Study: NCT02514447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Study: NCT04140695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID
Study: NCT04463199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniocervical flexion training
Description: PBU airbag was clipped together and folded in, fastened, and placed suboccipital. Uninflated pressure sensor was kept below the neck, so that it touched the occiput then inflated to a stable baseline pressure of 20 mmHg to just fill the space below the neck but not to push it into lordosis. Subjects were demonstrated the correct action of the deep cervical flexors that is gentle nodding of head as if saying yes.
Study: NCT01559259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen/acetaminophen
Description: Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen/acetaminophen
Description: Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen/acetaminophen
Description: Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Two caplets of ibuprofen 200 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two caplets of placebo
Study: NCT04165941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DRI cell therapy
Description: Drug Resistant Immunotherapy with gamma delta modified T cells to be resistance to temozolomide will be infused into the surgical cavity following the completion of standard concurrent radiation and chemotherapy with temozolomide.
Study: NCT04098432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
Study: NCT03734653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Testosterone
Description: Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care, Enzalutamide
Description: Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.
Study: NCT02514447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Study: NCT02616926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic resection
Description: Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
Study: NCT04178252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mask
Description: investigators will add eye mask to standard treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mask
Description: investigators will add eye mask to standard treatment
Study: NCT02514447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02616926

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: RFA will be performed 1 week after TACE.